Pre-made Modakafusp biosimilar ( Whole mAb Fusion, anti-ADPRC therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-352
Anti-ADPRC therapeutic antibody (Pre-made Modakafusp biosimilar,Whole mAb Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Modakafusp alfa (formerly TAK 573 or TEV 48573) is a CD38 targeted antibody (IgG4) fused with attenuated interferon alpha (IFN-α), being developed by Takeda, through its wholly-owned subsidiary Millennium Pharmaceuticals, for the treatment of multiple myeloma and solid tumours.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-ADPRC therapeutic antibody (Pre-made Modakafusp biosimilar,Whole mAb Fusion)|
|Format||Whole mAb Fusion|
|Highest_Clin_Trial (Jan '20)||Phase-I/II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Multiple myeloma|